Do Yeon Cho

Dr. Do Yeon Cho


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in Cell Host & Microbe
Verified
Journal Article
Closed access
MYMiling Yan
Miling Yan
SPSünje Johanna Pamp
Sünje Johanna Pamp
JFJulia Fukuyama
Julia Fukuyama
PHPeter H. Hwang
Peter H. Hwang
DCDo Yeon Cho
Do Yeon Cho
DRDavid A. Relman
David A. Relman

16 May 2017 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
WTWilliam Teachey
William Teachey
JGJessica Grayson
Jessica Grayson
DCDo Yeon Cho
Do Yeon Cho
KRKristen O. Riley
Kristen O. Riley
BWBradford Woodworth
Bradford Woodworth

1 November 2008 in American Journal of Rhinology
Verified
Journal Article
Closed access
DCDo Yeon Cho
Do Yeon Cho
PHPeter H. Hwang
Peter H. Hwang
Background: In patients with chronically diseased maxillary sinuses, poor mucociliary clearance may result from long-standing inflammation or scarring from previous surgery. This subset of patients often has persistent sinus disease despite medical therapy and adequate antrostomy. Endoscopic maxillary mega-antrostomy (EMMA) is a mucosal sparing technique that facilitates mucus clearance and sinus irrigation in terminally dysfunctional maxillary sinuses. EMMA involves extending the antrostomy through the posterior half of the inferior turbinate down to the floor of the nose, creating a significantly enlarged antrostomy. This study describes our results of EMMA in recalcitrant maxillary sinusitis. Methods: A retrospective review was performed of patients who underwent EMMA for recalcitrant maxillary sinusitis between July 2005 and September 2007. We studied diagnoses, comorbid factors, clinical efficacy, revision rate, and complications. Results: Twenty-eight patients (average age, 48 years) underwent 42 EMMAs for recalcitrant maxillary sinusitis. Average follow-up was 11 months. All patients had previous maxillary sinus surgery (mean = 2.3). Relevant comorbid factors included prior Caldwell-Luc or maxillofacial surgery (16/42), cystic fibrosis (11/42), asthma (11/42), and IgG deficiency (3/42). The most common symptoms reported were facial pain/pressure and purulent rhinorrhea. At the time of the most recent postoperative examination, 74% of patients reported complete resolution of symptoms while 26% reported partial symptomatic improvement. There were no complications and the revision rate was 0%. Conclusion: Maxillary sinuses that appear to be terminally diseased may be rehabilitated surgically without the need for surgical stripping. EMMA is an effective and safe treatment option for the management of recalcitrant maxillary sinus disease.

1 May 2020 in Immunology and Allergy Clinics of North America
Verified
Journal Article
Closed access
DCDo Yeon Cho
Do Yeon Cho
RHRyan C. Hunter
Ryan C. Hunter
VRVijay R. Ramakrishnan
Vijay R. Ramakrishnan

16 February 2017 in International Forum of Allergy & Rhinology
Verified
Journal Article
Closed access
PDF file
JGJessica W. Grayson
Jessica W. Grayson
HJHari Jeyarajan
Hari Jeyarajan
EIElisa A. Illing
Elisa A. Illing
DCDo Yeon Cho
Do Yeon Cho
KRKristen O. Riley
Kristen O. Riley
BWBradford A. Woodworth
Bradford A. Woodworth

2 February 2016 in International Forum of Allergy & Rhinology
Verified
Journal Article
Closed access
PDF file
EIElisa A. Illing
Elisa A. Illing
DCDo Yeon Cho
Do Yeon Cho
KRKristen O. Riley
Kristen O. Riley
BWBradford Woodworth
Bradford Woodworth